Stocks and Investing
Stocks and Investing
Thu, May 7, 2020
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Wed, May 6, 2020
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Alan Carr Maintained (ALNY) at Strong Buy with Increased Target to $160 on, May 6th, 2020
Published on 2024-10-27 05:31:34 - WOPRAI, Alan Carr
Alan Carr of Needham, Maintained "Alnylam Pharmaceuticals, Inc." (ALNY) at Strong Buy with Increased Target from $135 to $160 on, May 6th, 2020.
Alan has made no other calls on ALNY in the last 4 months.
There are 2 other peers that have a rating on ALNY. Out of the 2 peers that are also analyzing ALNY, 0 agree with Alan's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Alan
- Christopher Marai of "Nomura" Maintained at Sell and Held Target at $74 on, Tuesday, April 14th, 2020
- David Lebovitz of "Morgan Stanley" Maintained at Buy with Decreased Target to $148 on, Friday, February 7th, 2020
Contributing Sources